Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7760978 | 0.88 | WNT3A (0.37) | WNT3ATNKS2 | |
| SCHEMBL7762781 | 0.69 | ACHE (0.37) | — | |
| SCHEMBL7760964 | 0.67 | ATM (0.32) | — | |
| SCHEMBL26020376 | 0.66 | WNT3A (0.39) | WNT3ATNKS2 | |
| SCHEMBL18711686 | 0.65 | HTR2A (0.31) | — | |
| SCHEMBL19362369 | 0.64 | — | — | |
| SCHEMBL7760996 | 0.62 | — | — | |
| SCHEMBL27114737 | 0.62 | — | — | |
| SCHEMBL26026426 | 0.62 | TNKS2 (0.34) | TNKSWNT3ATNKS2 | |
| SCHEMBL31128515 | 0.62 | TNKS2 (0.50) | TNKSWNT3ATNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | TNKS 234/4885WNT3A 2464/4885TNKS2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.